Inactive Instrument

Spotlight Innovation Inc.

STLT

US8492071050

Biotechnology & Medical Research

Spotlight Innovation, Inc. Announces Resignation of David Hostelley as Chief Financial Officer, Effective August 31, 2015

August 31, 2015 at 12:19 pm

Effective August 31, 2015, David Hostelley resigned as Chief Financial Officer of Spotlight Innovation Inc. due to personal reasons.

Latest news about Spotlight Innovation Inc.

Spotlight Innovation Inc. Announces Management Changes	18-10-10	CI
Spotlight Innovation Enters into Research Agreement with Indiana University	17-08-17	CI
Spotlight Innovation Inc. Enters into Sponsored Research Agreement with The Brigham and Women's Hospital Inc	17-06-27	CI
Spotlight Innovation Inc. announced that it has received $0.4 million in funding	17-05-30	CI
Spotlight Innovation Inc. Announces Management Changes	17-05-23	CI
Spotlight Innovation Licenses Additional Anti-Zika Virus Compounds	17-02-15	CI
Spotlight Innovation Inc. Enters into a Second Exclusive License Agreement with Florida State University Research Foundation	17-01-31	CI
Spotlight Innovation Inc. Announces Executive Changes	17-01-04	CI
Spotlight Innovation Inc. announced that it has received $0.17 million in funding from K4 Enterprises, LLC	16-12-29	CI
Spotlight Innovation Inc. announced that it has received $0.83 million in funding from K4 Enterprises, LLC	16-12-15	CI
Spotlight Innovation Inc. Appoints Chitra Edwin as Senior Vice President of Regulatory Affairs and Compliance	16-12-08	CI
Spotlight Innovation Announces Formation of Scientific Advisory Board	16-12-06	CI
Spotlight Innovation Announces Strategic Investment in Solx, Inc	16-11-30	CI
SOLX, Inc. announced that it has received $0.8 million in funding from Spotlight Innovation Inc.	16-11-29	CI
Spotlight Innovation Inc. Enters into Exclusive License Agreement with Florida State University Research Foundation	16-11-10	CI
Spotlight Innovation Announces Appointment to Scientific Advisory Board	16-10-20	CI
Spotlight Innovation Inc. Enters into License Agreement with Indiana University Research and Technology Corporation	16-10-17	CI
Spotlight Innovation Inc. Establishes Subsidiary as Caretta Therapeutics	16-10-06	CI
Spotlight Innovation Inc. Enters into Sponsored Research Agreement with Florida State University	16-09-26	CI
Spotlight Innovation Appoints Cassandra K. MacArthur as Senior Vice President of Regulatory Affairs and Compliance	16-09-01	CI
Spotlight Innovation Inc. announced that it expects to receive $2.5 million in funding	16-08-30	CI
Spotlight Innovation Inc. Appoints Geoffrey Laff as Vice President of Scientific Strategy	16-07-14	CI
Spotlight Innovation Inc. Announces Board Resignations	16-06-16	CI
Spotlight Innovation Inc. Enters into an Agreement with Maitland Labs to Establish its Drug Production and Product Development Facilities	16-06-10	CI
Spotlight Innovation Inc. announced that it has received $0.85 million in funding	16-03-30	CI

Chart Spotlight Innovation Inc.

Duration

Period

More charts

Spotlight Innovation Inc. is a pharmaceutical company. The Company is focused on acquiring the intellectual property rights to therapeutics designed to address unmet medical needs. As of June 30, 2017, the Company had four subsidiaries: Celtic Biotech Iowa, Inc. (Celtic Iowa), Caretta Therapeutics, LLC (Caretta), SMA Therapeutics, LLC (SMA), and Zika Therapeutics, LLC (Zika). It is focused on various diseases, including cancer, pain management, Zika Virus infection and spinal muscular atrophy. The Company, through Celtic Iowa, holds interest in Celtic Biotech Limited, which is engaged in developing specialized compounds derived from snake venom, for the treatment of solid cancers and cancer imaging. The Company, through Caretta, is focused on developing the commercialization of over-the-counter products. It is also engaged in discovery, synthetic modification, and preclinical validation of drug-like compounds intended to treat patients with Zika virus infection.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs